Why the study?
Does the measurement of natriuretic peptides improve risk stratification for prognosis in patients with acute coronary syndrome?
Does the measurement of natriuretic peptides improve risk stratification for prognosis in patients with acute coronary syndrome?
Natriuretic peptides provide valuable prognostic information for mortality and heart failure risk in ACS patients, improving risk stratification when added to troponin and other markers.
May aid ACS mortality and incident HF risk stratification; leaves open prospective trials of clinical utility.
Levels of natriuretic peptides, including B-type natriuretic peptide and N-terminal prohormone brain natriuretic peptide, are strong independent predictors of prognosis in acute coronary syndrome (ACS). They are associated with short- and long-term mortality and with the risk of new-onset heart failure, above and beyond the conventional risk factors. Myocardial ischemia and ventricular wall stress are triggers for the release of natriuretic peptides, and although the latter are associated with the severity of the underlying coronary artery disease, they fail to predict recurrent nonfatal ACS. In conclusion, natriuretic peptide values may improve risk stratification in ACS when used in addition to troponin levels and other prognostic markers, but more data are needed to define their role in ACS therapy.
No takes yet. Share an insight, caveat, or question.
Farmakis et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: